CL2019002899A1 - Formulaciones con mayor estabilidad y biodisponibilidad para administración de (e)-2,6-dialcoxiestiril bencilsulfonas sustituidas en 4. - Google Patents

Formulaciones con mayor estabilidad y biodisponibilidad para administración de (e)-2,6-dialcoxiestiril bencilsulfonas sustituidas en 4.

Info

Publication number
CL2019002899A1
CL2019002899A1 CL2019002899A CL2019002899A CL2019002899A1 CL 2019002899 A1 CL2019002899 A1 CL 2019002899A1 CL 2019002899 A CL2019002899 A CL 2019002899A CL 2019002899 A CL2019002899 A CL 2019002899A CL 2019002899 A1 CL2019002899 A1 CL 2019002899A1
Authority
CL
Chile
Prior art keywords
dialkoxystyryl
benzylsulfones
bioavailability
formulations
administration
Prior art date
Application number
CL2019002899A
Other languages
English (en)
Inventor
Manoj Maniar
Original Assignee
Onconova Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59856606&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2019002899(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Onconova Therapeutics Inc filed Critical Onconova Therapeutics Inc
Publication of CL2019002899A1 publication Critical patent/CL2019002899A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE DESCRIBEN COMPOSICIONES FARMACÉUTICAS DE (E)-2,4,6-TRIMETOXIESTIRIL-3-[(CARBOXIMETIL)AMINO]-4-METOXIBENCILSULFONA Y SUS FARMACÉUTICAMENTE ACEPTABLES, ASÍ COMO MÉTODOS DE SU USO, Y UN RÉGIMEN DE DOSIS DE (E)-2,4,6-TRIMETOXIESTIRIL-3-[(CARBOXIMETIL)AMINO]-4-METOXIBENCILSULFONA, SAL DE SODIO PARA REDUCIR LA INCIDENCIA DE TOXICIDAD UROTELIAL.
CL2019002899A 2017-04-13 2019-10-11 Formulaciones con mayor estabilidad y biodisponibilidad para administración de (e)-2,6-dialcoxiestiril bencilsulfonas sustituidas en 4. CL2019002899A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762485355P 2017-04-13 2017-04-13
PCT/US2017/048890 WO2018190897A1 (en) 2017-04-13 2017-08-28 Formulation of (e)-2,4,6-trimethoxystyryl-3-[(carboxymethyl)amino]-4- methoxybenzylsulphone with enhanced stability and bioavailability
US15/688,320 US10098862B1 (en) 2017-04-13 2017-08-28 Formulations with enhanced stability and bioavailability for administration of (E)-2,6-dialkoxystyryl 4-substituted benzylsulfones

Publications (1)

Publication Number Publication Date
CL2019002899A1 true CL2019002899A1 (es) 2020-02-28

Family

ID=59856606

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019002899A CL2019002899A1 (es) 2017-04-13 2019-10-11 Formulaciones con mayor estabilidad y biodisponibilidad para administración de (e)-2,6-dialcoxiestiril bencilsulfonas sustituidas en 4.

Country Status (19)

Country Link
US (1) US10098862B1 (es)
EP (3) EP3609471B1 (es)
JP (1) JP7202313B2 (es)
KR (1) KR102643626B1 (es)
CN (2) CN110536678A (es)
AR (1) AR109503A1 (es)
AU (1) AU2018253291B2 (es)
BR (1) BR112019021445A2 (es)
CA (1) CA3058664A1 (es)
CL (1) CL2019002899A1 (es)
CO (1) CO2019011299A2 (es)
EA (1) EA201992436A1 (es)
ES (2) ES2941538T3 (es)
IL (2) IL289806B2 (es)
MX (1) MX2022011860A (es)
TW (2) TWI809721B (es)
UY (1) UY37380A (es)
WO (2) WO2018190897A1 (es)
ZA (2) ZA201906671B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11382877B2 (en) 2017-04-13 2022-07-12 Onconova Therapeutics, Inc. Formulation of (E)-2,4,6-trimethoxystyryl-3-[(carboxymethyl)amino]-4-methoxybenzylsulphone with enhanced stability and bioavailability

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100972131B1 (ko) 2002-02-28 2010-07-26 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 증식성 질병 치료용 아미노-치환（ｅ）-2,6-디알콕시스티릴 4-치환-벤질설폰
WO2006010152A2 (en) * 2004-07-19 2006-01-26 Onconova Therapeutics, Inc. Formulations for parenteral administration of (e)-2,6-dialkoxystryryl 4-substituted benzylsulfones
JP5278968B2 (ja) 2006-08-30 2013-09-04 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション 骨髄異形性症候群及び急性骨髄性白血病の治療のための組成物及び方法
EP2124569A4 (en) 2007-01-16 2013-02-27 Onconova Therapeutics Inc FORMULATIONS FOR THE PARENTERAL ADMINISTRATION OF (E) -2,6-DIALKOXY STYRYL-4-SUBSTITUTED BENZYL SULPHONES
CN104203235B (zh) 2012-02-14 2018-11-23 赛多斯有限责任公司 苯达莫司汀的制剂
EP2928456B1 (en) * 2012-12-07 2021-02-03 Onconova Therapeutics, Inc. Treatment of hematological cancer refractory to an anti-cancer agent

Also Published As

Publication number Publication date
WO2018190897A1 (en) 2018-10-18
US20180296513A1 (en) 2018-10-18
BR112019021445A2 (pt) 2020-05-05
CA3058664A1 (en) 2018-10-18
EP4193988A1 (en) 2023-06-14
ES2926042T3 (es) 2022-10-21
ZA201906671B (en) 2022-03-30
EP3609471B1 (en) 2023-01-04
US10098862B1 (en) 2018-10-16
TW201836597A (zh) 2018-10-16
IL269757B (en) 2022-08-01
CN110536678A (zh) 2019-12-03
IL269757A (en) 2019-11-28
IL289806B2 (en) 2024-06-01
IL289806B1 (en) 2024-02-01
CN116637095A (zh) 2023-08-25
KR102643626B1 (ko) 2024-03-06
WO2018191634A4 (en) 2019-06-20
IL289806A (en) 2022-03-01
KR20190134705A (ko) 2019-12-04
EP3733163B1 (en) 2022-06-08
JP2020516665A (ja) 2020-06-11
ES2941538T3 (es) 2023-05-23
WO2018191634A3 (en) 2019-04-11
AU2018253291B2 (en) 2024-05-02
UY37380A (es) 2018-10-31
TWI759459B (zh) 2022-04-01
WO2018191634A2 (en) 2018-10-18
EA201992436A1 (ru) 2020-03-30
EP3733163A1 (en) 2020-11-04
AU2018253291A1 (en) 2019-10-24
MX2022011860A (es) 2022-10-20
TW202222303A (zh) 2022-06-16
CO2019011299A2 (es) 2020-02-18
TWI809721B (zh) 2023-07-21
EP3733163B8 (en) 2022-09-28
ZA202107580B (en) 2023-11-29
AR109503A1 (es) 2018-12-19
JP7202313B2 (ja) 2023-01-11
EP4193988B1 (en) 2024-06-05
EP3609471A2 (en) 2020-02-19

Similar Documents

Publication Publication Date Title
NI202000078A (es) Compuestos heteroaril tetracíclicos
ECSP19075134A (es) Sistemas de administración de liberación sostenida que comprenden ligantes que no dejan huellas
BR112022008375A2 (pt) Composto cíclico heterocíclico fundido substituído, método de preparação e uso farmacêutico deste
UY37645A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
BR112015018087A8 (pt) composto, composição farmacêutica e uso
UY37741A (es) Derivados de indolina sustituidos como inhibidores de la replicación del virus del dengue
UY35586A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
ECSP17007208A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
UY39706A (es) Derivados de (1hindol- 3-il)-2-(4-cloro-2-metoxi-fenil)-2-((3-metoxi-5-(metilsulfonil) fenil)amino)etanona como inhibidores de la replicación del virus del dengue
AR104984A1 (es) Compuestos selectivos para pyy y sus usos
MY196788A (en) Fused tricyclic ?-amino acid derivative, preparation method therefor, and medical use thereof
UY37742A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
PH12019500188A1 (en) Piperidine cxcr7 receptor modulators
UY35275A (es) Derivados de aminopirazina
MX2020003732A (es) Derivado de anillo fusionado como inhibidor del receptor a2a.
CL2018000363A1 (es) Derivados del ácido 5-(n-bencil-tetrahidroisoquinolin-6-il)-piridin-3-il acético como inhibidores de la replicación del virus de la inmunodeficiencia humana.
EA201791600A1 (ru) Производные гидроксиалкилпиперазина в качестве модуляторов cxcr3 рецептора
CY1119537T1 (el) Ρυθμιστες υποδοχεα cxcr 7
BR112017020081A2 (pt) análogos deuterados de etifoxina, seus derivados e usos dos mesmos
EA201990501A1 (ru) Фармацевтическая композиция
CU20210077A7 (es) Extractos bacterianos estables como fármacos
TR201901977T4 (tr) Cxcr3 reseptörü modülatörleri olarak (r)-2-metil-piperazin türevleri.
ZA202103090B (en) Pharmaceutical formulations of cyclosporine analogs
CL2019002899A1 (es) Formulaciones con mayor estabilidad y biodisponibilidad para administración de (e)-2,6-dialcoxiestiril bencilsulfonas sustituidas en 4.
EA202090978A1 (ru) Новые макроциклические производные, способ их получения и содержащие их фармацевтические композиции